Research Analysts Set Expectations for TSE:MDP Q4 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Bloom Burton decreased their Q4 2025 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.01. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Other equities research analysts also recently issued research reports about the company. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Price Performance

MDP stock opened at C$4.47 on Friday. The company’s 50-day moving average is C$3.14 and its 200-day moving average is C$2.69. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The stock has a market capitalization of C$109.65 million, a PE ratio of 89.40 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.